Sage Therapeutics said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 ...

After a year of disappointing drug trial results, Sage Therapeutics Inc. is slashing its headcount and shaking up its ...

Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment ...

The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term ...

Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple ...

Sage Therapeutics announces a reorganization to support product launch and pipeline development, resulting in a workforce ...

TD Cowen analyst Ritu Baral has maintained their neutral stance on SAGE stock, giving a Hold rating on October 17. Ritu Baral has given his ...

Scotiabank的分析师指出，市场基本上已经预料到了这次试验的失败结果。然而，他们认为更重要的后果是，这为Sage Therapeutics进行重大重组铺平了道路。该公司强调，即使dalzanemdor在今年晚些时候即将公布结果的亨廷顿氏症2期DIMENSION研究中取得成功，由于该领域竞争日益激烈，仍然存在显著的开发风险。

Sage Potash Corp., (TSXV: SAGE) (OTC: SGPTF) ("Sage" or the "Company") is pleased to announce that Rod Reum has been ...

周三，贝尔德(Baird)调整了对Sage Therapeutics (NASDAQ:SAGE)股票的展望，将目标价从之前的13.00美元下调至9.00美元，同时维持对该股的中性评级。这一决定是在dalzanemdor用于阿尔茨海默病的2期LIGHTWAVE试验失败的公告之后做出的。试验的结果使投资者的全部注意力转向了该公司的另一个前景，即Zurzuvae。 LIGHTWAVE试验是Sage Th ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

The new hires bring global partnership and marketing expertise to support its mission of financial wellbeing and credit ...